介素-6在胆道癌症中的当前作用和未来前景
Meng Zhou1, Ruisi Na1, Shihui Lai1
1Key Laboratory of Molecular Oncology of Heilongjiang Province, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang, China.
Cytokine
|June 18, 2023
概括
介素-6 (IL-6) 驱动胆道癌 (BTC) 的生长和转移. 在BTC治疗中,阻断IL-6可能会增强免疫反应,并克服对免疫检查点抑制剂 (ICI) 的耐药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 胆道癌 (BTC) 是一组侵袭性癌症,包括肝内胆道癌 (iCCA),周围胆道癌 (pCCA),远端胆道癌 (dCCA) 和胆囊癌 (GBC).
- 慢性炎症和细胞因子,特别是IN-6 (IL-6),对BTC致癌,增殖,血管生成和转移有显著的贡献.
- IL-6是一种关键的细胞因子,与BTC进展有关,并作为诊断,预后和监测的潜在生物标志物.
研究的目的:
- 系统地审查IL-6在BTC的发展和进展中的核心作用.
- 总结IL-6阻断可能提高BTC中免疫检查点抑制剂 (ICI) 疗效的潜在机制.
- 提出未来的治疗策略,包括IL-6通路抑制,以改善BTC中的ICI敏感性.
主要方法:
- 系统性文献审查,重点关注IL-6在BTC中的作用.
- 关于IL-6抗体及其对瘤微环境 (TME) 的影响的临床前证据分析.
- 研究分子途径,如mTOR,将IL-6与PD-L1表达等免疫逃避机制联系起来.
主要成果:
- IL-6在促进BTC瘤发生,血管生成,增殖和转移方面发挥着至关重要的作用.
- 通过调节免疫细胞透和免疫检查点表达,IL-6抗体显示出使瘤对ICI敏感的潜力.
- 已经证明IL-6可以通过iCCA中的mTOR途径诱导编程死亡配体1 (PD-L1) 的表达,这表明免疫逃避的机制.
结论:
- IL-6是BTC的关键驱动因素,也是潜在的治疗点.
- 将IL-6阻塞与ICI结合起来可能是一个有希望的策略,以克服治疗耐药性并改善BTC的结果.
- 需要进一步的研究来验证IL-6向疗法的有效性,以提高胆道癌症的ICI反应.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
01:17Chronic Bowel Disorders: Introduction
492
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
492
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177